Pheochromocytoma synonyms

Pheochromocytoma is a rare, catecholamine-secreting tumor of the adrenal medulla, most commonly referred to by this name in modern clinical practice. While it is sometimes historically or colloquially called an "adrenal paraganglioma," the term pheochromocytoma is the standardized medical nomenclature used across major classification systems like the ICD-10 and Orphanet to ensure diagnostic clarity.

What are the common synonyms and historical names for Pheochromocytoma?

In medical literature, pheochromocytoma is occasionally referred to by names that reflect its biological origin or historical discovery. You may encounter the term "adrenal paraganglioma" in pathology reports, as pheochromocytoma is essentially a paraganglioma that arises specifically from the adrenal medulla. Older literature may sometimes use the term "chromaffinoma," derived from the "chromaffin" cells that make up the tumor. Additionally, because these tumors secrete hormones like adrenaline and noradrenaline, they have historically been described as "medullary tumors of the adrenal gland." Understanding these variations is essential for patients navigating legacy medical records or research databases.

Why does Pheochromocytoma have multiple names?

The variety of names for pheochromocytoma stems from the evolution of endocrinology and surgical pathology. Historically, the name was derived from the Greek words phaios (dark/dusky) and chroma (color), referring to the dark brown color the tumor tissue turns when stained with chromium salts—a process known as the chromaffin reaction. As our understanding of tumor biology grew, clinicians began to classify these tumors based on their anatomical location and genetic expression. Today, the medical community prefers the term pheochromocytoma to distinguish adrenal-based tumors from extra-adrenal paragangliomas, which occur outside the adrenal gland.

How is Pheochromocytoma classified in medical systems?

To maintain consistency in clinical coding and research, major health organizations utilize specific identifiers for pheochromocytoma. Standardizing this terminology helps the 165 members of the DiseaseMaps.org community share experiences and find relevant clinical trials. The primary classification systems include:

• ICD-10/ICD-11: C74.1 (Malignant neoplasm of medulla of adrenal gland) or D35.0 (Benign neoplasm of adrenal gland).


• Orphanet: ORPHA:713 (Pheochromocytoma).


• OMIM: #171300 (Pheochromocytoma, susceptibility to).

Which name should patients and clinicians use?

While regional differences may exist in how doctors dictate notes, pheochromocytoma remains the globally accepted clinical standard. When communicating with your healthcare team, using the term pheochromocytoma is the most effective way to ensure accuracy in your electronic health record (EHR) and to facilitate communication between specialists, such as endocrinologists, surgeons, and genetic counselors. If you see terms like "adrenal paraganglioma" on a pathology report, it is simply a more descriptive anatomical classification, but it does not change the fundamental diagnosis.

Next steps

• Consult an endocrinologist or an endocrine surgeon to discuss your specific pathology report and diagnosis.


• Request a referral to a clinical geneticist, as approximately 30-40% of cases are associated with hereditary genetic syndromes.


• Connect with the 165 members of the DiseaseMaps.org community to share experiences and find peer support.


• Maintain a copy of your diagnostic reports using the term pheochromocytoma to ensure consistency across all medical facilities.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pheochromocytoma.


• Orphanet: Rare Disease Database (ORPHA:713).


• Online Mendelian Inheritance in Man (OMIM): Entry #171300.


• The Pheochromocytoma and Paraganglioma (Pheo Para) Alliance.